북미 제약용 분리기 시장 – 2029년까지의 산업 동향 및 예측

TOC 요청 TOC 요청 분석가에게 문의 분석가에게 문의 지금 구매 지금 구매 구매하기 전에 문의 구매하기 전에 문의 무료 샘플 보고서 무료 샘플 보고서

북미 제약용 분리기 시장 – 2029년까지의 산업 동향 및 예측

  • Healthcare
  • Published Report
  • Nov 2022
  • North America
  • 350 Pages
  • 테이블 수: 95
  • 그림 수: 47

북미 제약용 분리기 시장, 유형별(무균 분리기, 격리 분리기, 생물학적 분리기, 샘플링 및 계량 분리기, 활성 제약 성분(API) 제조 분리기, 방사성 의약품 분리기, 생산 분리기, 기타), 시스템 유형(폐쇄형 시스템, 개방형 시스템), 압력(양압, 음압), 구성(바닥형, 모듈형, 모바일형, 콤팩트형, 테이블탑형, 휴대용 , 기타), 응용 분야(멸균 검사, 제조, 샘플링/계량/유통, 의료 기기 제조), 최종 사용자(병원, 진단 실험실, 학술 및 연구 기관, 제약 및 생명 공학 회사, 계약 연구 기관, 기타), 유통 채널(직접 입찰, 소매 판매, 제3자 유통업체) 산업 동향 및 2029년까지의 예측.

북미 제약용 분리기 시장

북미 제약용 분리기 시장 분석 및 통찰력

제약용 분리기는 제약 산업에서 오염 없는 장벽 시스템으로 사용됩니다. 미생물 검사, 세포 치료 처리, 첨단 제약(ATMP) 제조, 멸균 주사 제품의 계량, 포장 및 유통은 제약용 분리기의 몇 가지 응용 분야일 뿐입니다. 제약용 분리기의 사용은 개발도상국과 선진국에서 제약 시장의 지속적인 성장과 혁신적인 치료법을 생산하기 위한 R&D 지출 증가로 인해 촉진되었습니다. 첨단 의료용 절연체와 제약 산업의 요구 사항으로 인해 주요 제조업체는 의료용 절연체 산업을 성장시켰습니다. 유해 화합물의 사용 증가, 비준수 비용 증가, 연구실 증가는 예측 기간 동안 제약용 분리기 시장을 주도하는 중요한 요인입니다.

북미 제약용 분리기 시장

북미 제약용 분리기 시장

그러나 대부분의 전문가들은 규제 기관이 더 이상 제약용 절연체 개발과 같은 획기적인 발전을 방해할 수 없다는 데 동의하지 않습니다.

Data Bridge Market Research는 북미 제약용 아이솔레이터 시장이 2029년까지 2,627.64백만 달러에 도달할 것으로 예상되며, 예측 기간 동안 CAGR은 14.6%입니다. 유형은 이 지역에서 제약용 아이솔레이터에 대한 수요가 빠르게 증가함에 따라 시장에서 가장 큰 유형 세그먼트를 차지합니다. 이 시장 보고서는 또한 가격 분석, 특허 분석 및 기술 발전에 대한 심층적인 내용을 다룹니다.

보고서 메트릭

세부

예측 기간

2022년부터 2029년까지

기준 연도

2021

역사적 연도

2020 (2019-2014까지 사용자 정의 가능)

양적 단위

매출은 백만 달러, 볼륨은 단위, 가격은 달러로 표시됨

다루는 세그먼트

By Type (Aseptic Isolators, Containment Isolators, Bio Isolators, Sampling And Weighing Isolators, Active Pharmaceutical Ingredient (API) Manufacturing Isolators, Radiopharmaceutical Isolators, Production Isolators, Others), System Type (Closed System, Open System), Pressure (Positive Pressure, Negative Pressure), Configuration (Floor Standing, Modular, Mobile, Compact, Table Top, Portable, Others), Application (Sterility Testing, Manufacturing, Sampling/ Weighing/ Distribution, Medical Device Manufacturing), End User (Hospitals, Diagnostic Laboratories, Academic And Research Institutes, Pharmaceutical And Biotechnology Companies, Contract Research Organizations, Others), Distribution Channel (Direct Tender, Retail Sales, Third Party Distributors).

Countries Covered

U.S., Canada, and Mexico

Market Players Covered

Getinge, SKAN AG, Hosokawa micron ltd, Gelman Singapore, Azbil Corporation, Germfree Laboratories, Inc., M. Braun Inertgas-Systeme Gmbh, Nuaire, Iteco S.R.L., Comecer S.P.A., Hecht Technologie Gmbh, Steriline S.R.L., Envair Limited, Tema Sinergie S.P.A, Schematic Engineering Industries, Chiyoda Corporation, Chamunda Pharma Machinery Pvt. Ltd, Bioquell (Ecolab Solution), Jacomex, Fedegari Autoclavi S.p.A., LAF Technologies,  ISO Tech Design, Cytiva, Esco Pharma among others.

North America Pharmaceutical Isolator Market Definition

The isolation concept, is quite known in the pharmaceutical industry, protects the process from the Operator and or the operator from the process, while protecting the environment. The key to containment, is minimal exposure. By controlling the exposure range below the hazard level set for the compound, the Operator and the environment are properly protected. Hence, the product is protected and therefore a key regulatory issue is addressed. A pharmaceutical isolator is a sealed bacterial enclosure used in the pharmaceutical surrounding for aseptic filling and toxic process. It is made of a perfectly sterile main isolator where the products are handled, stored or packaged using shoulder-high gloves placed on one of the walls. The pharmaceutical isolator enables the control and containment of pharmaceutical processes. The conditions required for working of a pharmaceutical isolator are sterile environment and free of viable microorganisms. A pharmaceutical isolator ensures that production area and aseptic environment are placed in separate positions. A pharmaceutical industry isolator is cost effective and efficient, in comparison to cleanrooms for the pharmaceutical industry in an aseptic environment. It creates a controlled atmosphere during the microbial and drug production process by adjusting with the different standards certification standard required for isolators and restricted access barriers. It ensures the protection of the product, the operators and the environment at the same time.

The abundant applications of pharmaceutical isolators, vary for production and control purposes. It is used while handling, transferring or packing solid semi-solid or powder pharma drugs, handling and filing solutions and infusions. The pharmaceutical isolators are applied in sterility testing, aseptic handling of tissues or biological production systems or pathogenic samples, etc. It can be used for the production and control of drugs and pharmaceutical products. The surge in demand for the isolators across pharmaceutical and biotechnology industry, along with low operational cost, high maintenance of aseptic condition in the production of pharmaceutical products and growing demand of biopharmaceutical industry are the factors expected to drive the market growth, in the forecast period.

Also, strategic initiative by market players, technological progressions in pharmaceutical isolators, high sterility assurance and increasing investment for healthcare infrastructure. These factors increase in the demand for pharmaceutical isolators market.

North America Pharmaceutical Isolator Market Dynamics

This section deals with understanding the market drivers, advantages, opportunities, restraints, and challenges. All of this is discussed in detail below:    

Drivers

Growing demand for the pharmaceutical isolators across booming pharmaceutical

Pharmaceutical isolator is a separative device that divides a pharmaceutical procedure or activity from the operator and the adjacent environment. It is used for various purposes such as:

  • Providing a categorized aseptic environment for an activity or procedure and guarding it from microbial and non-microbial contamination rising from the operator and adjacent environment which is referred to product protection.
  • Protective product from contamination produced by other product and procedure, moreover at the same time or during earlier operations. This is referred to as safeguard against method generated contamination or cross- contamination.

The Increasing contamination problems in the manufacturing unit in which comes isolator that create a demand for Pharmaceutical isolator that helps in contamination and de-contamination.

  • Low operational cost of pharmaceutical isolators

Enclosures that are sealed to some standard of leak tightness that comprises inside qualified controlled environment, at modification with the surrounding conditions isolator application reaches from R&D by the production of pharmaceuticals to laboratory use, especially for the microbiological quality control. Whereas pharmaceutical aseptic production has extremely high standards of cleanness almost completely particle free and germ free environments for the aseptic production.

Due to growth in the pharma industry and the widening product range more and more manufacturers and suppliers needs to think about investments in latest added technologies of the clean room technology.

Aseptic processing of the pharmaceutical drugs is the major factor need to be included in good manufacturing practices meeting the government regulations. The high cost of the maintenance of the aseptic condition by clean room technology which is around 62% higher than the pharmaceutical isolators, shifting the manufacturers to acquire isolator’s technology and constraining the overall manufacturing cost of the pharmaceutical products.

Restraint

Stringent governmental regulations

Active Pharmaceutical Ingredients (API) and intermediates for pharmaceutical use (for instance biological, radiopharmaceutical, and pharmaceutical) and those used to production drugs for clinical trials are regulated under the Divisions 1A and 2, Part C of the Food and Drug Regulations.

  • Division 1A, Part C of the Food and Drug Regulations describes activities for which Good Manufacturing Practices (GMP) compliance is required and must be demonstrated prior to the issuance of an API establishment license (EL).
  • Division 2, Part C of the Food and Drug Regulations defines the requirements for the GMP of APIs and API intermediates, which are interpreted in the present guidance document.

Due to this strict regulation by the government that has to be followed for the production by the Good Manufacturing Practices (GMP) Guidelines for Active Pharmaceutical Ingredients (API) - (GUI-0104) which constraining the market growth rate.

Opportunity

  • Strategic initiatives by market players

The rise in the pharmaceutical isolators market increases the need for strategic business ideas. It includes a partnership, business expansion, and other development. The rising demand for pharmaceuticals is significantly increasing the demand for excipient and to cope with this demand companies are building new manufacturing sites among other strategic initiatives.

These strategic initiatives such as product launches, agreement and business expansion by the major market player will boost the pharmaceutical isolator market growth and is expected to act as an opportunity for the North America medical display market.

Challenge

Lack of skilled expertise

The shortage of skilled expertise would challenge the pace of recovery and growth in one place. Often, the people who are unemployed in one place have skills that are in short supply elsewhere. Moreover, rapid technological advancement in this field also leads to lack of expertise.

Lack of skilled professionals while handling the pharmaceutical isolators poses a major challenge while selecting and developing the pharmaceutical isolators. The data by the Phys.org 2003 mentions the medical display industries are facing a shortage of workers due to increase demand of pharmaceutical isolators in Asia-Pacific region and severe scarcity of micro chips used in LED and LCD display, which increases the price lead times of LCD production.

As skill demands are too high, it has manifested as a challenge to retain and manage skill-specified professionals. Moreover, technological advancement is another aspect that leads to the increased demand for skilled professionals. Neurologists report significant unmet supportive care needs and barriers in their centers with only a small minority rating themselves as competently providing supportive care. There is an urgent need for education of neurologists and professionals for treatment of dementia and procuring available supportive care resources. Lack of trained and experienced professionals and persistent skill gaps limit the employability prospects and access to quality jobs. It is therefore apparent that availability of professionals equipped with adequate skills is expected to challenge the market growth.

Post-COVID-19 Impact on North America Pharmaceutical Isolator Market

The COVID-19 pandemic has become the world's most serious threat. It wreaked havoc in many stores and businesses around the world. The pandemic, on the other hand, has provided many opportunities for pharmaceutical and biopharmaceutical companies to expand their research and development activities to develop new vaccines against the new coronavirus. Companies are conducting clinical trials to try to stop the spread of the COVID-19 virus. Pharmaceutical insulator suppliers to biopharmaceutical organizations have more opportunities as the number of clinical trials increases.

Manufacturers are making various strategic decisions to bounce back post-COVID-19. The players are conducting multiple R&D activities and product launch and strategic partnerships to improve the technology and test results involved in the pharmaceutical medical display market.

Recent Developments

  • In June 2022, the company announced a partnership with Medical Supply Company (MSC) to market and service Jacomex equipment to the pharmaceutical and pharmaceutical industries in Ireland. MSC has many years of recognized expertise in the market with field teams closest to customers and company’s commercial team currently working abroad had the pleasure of welcoming Cian Murphy and finalizing the agreement between Jacomex and MSC. The beginning of a long and fruitful collaboration. This has helped the company to expand their business.
  • In January 2022, Clario partnered with XingImaging, a radiopharmaceutical production and positron emission tomography (PET) acquisition company, to deliver PET imaging clinical trials for testing novel therapeutics in China. The partnership offers to share the joint resources and neuroscience experts of Clario and XingImaging to expedite the startup of clinical trials and drug discovery in China.

North America Pharmaceutical Isolator Market Scope

North America pharmaceutical isolator market is segmented into type, pressure, application, configuration, system type, end user and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

NORTH AMERICA PHARMACEUTICAL ISOLATOR MARKET, BY TYPE

  • ASEPTIC ISOLATORS
  • CONTAINMENT ISOLATORS
  • BIO ISOLATORS
  • SAMPLING AND WEIGHING ISOLATORS
  • ACTIVE PHARMACEUTICAL INGREDIENT (API) MANUFACTURING ISOLATORS
  • RADIOPHARMACEUTICAL ISOLATORS
  • PRODUCTION ISOLATORS
  • OTHERS

On the basis of type, the North America pharmaceutical isolator market is segmented into aseptic isolators, containment isolators, bio isolators, sampling and weighing isolators, active pharmaceutical ingredient (API) manufacturing isolators, radiopharmaceutical isolators, production isolators, others.

NORTH AMERICA PHARMACEUTICAL ISOLATOR MARKET, BY SYSTEM TYPE

  • CLOSED SYSTEM
  • OPEN SYSTEM

On the basis of system type, the North America pharmaceutical isolator market is segmented into closed system, open system.

NORTH AMERICA PHARMACEUTICAL ISOLATOR MARKET, BY PRESSURE

  • POSITIVE PRESSURE
  • NEGATIVE PRESSURE

On the basis of pressure, the North America pharmaceutical isolator market is segmented into positive pressure and negative pressure.

NORTH AMERICA PHARMACEUTICAL ISOLATOR MARKET, BY CONFIGURATION

  • FLOOR STANDING
  • MODULAR
  • MOBILE
  • COMPACT
  • TABLE TOP
  • PORTABLE
  • OTHERS

On the basis of configuration, the North America pharmaceutical isolator market is segmented into floor standing, modular, mobile, compact, table top, portable, others.

NORTH AMERICA PHARMACEUTICAL ISOLATOR MARKET, BY APPLICATION

  • STERILITY TESTING
  • MANUFACTURING
  • SAMPLING/ WEIGHING/ DISTRIBUTION
  • MEDICAL DEVICE MANUFACTURING
  • OTHERS

On the basis of application, the North America pharmaceutical isolator market is segmented into sterility testing, manufacturing, sampling/ weighing/ distribution, medical device manufacturing, others.

NORTH AMERICA PHARMACEUTICAL ISOLATOR MARKET, BY END USER

  • HOSPITALS
  • DIAGNOSTIC LABORATORIES
  • ACADEMIC AND RESEARCH INSTITUTES
  • PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES
  • CONTRACT RESEARCH ORGANIZATIONS
  • OTHERS

On the basis of end user, the North America pharmaceutical isolator market is segmented into hospitals, diagnostic laboratories, academic and research institutes, pharmaceutical and biotechnology companies, contract research organizations, others.

NORTH AMERICA PHARMACEUTICAL ISOLATOR MARKET, BY DISTRIBUTION CHANNEL

  • DIRECT TENDER
  • RETAIL SALES
  • THIRD PARTY DISTRIBUTORS

제약용 아이솔레이터 시장

On the basis of distribution channel, the North America pharmaceutical isolator market is segmented into direct tender, retail sales, third party distributors.

North America Pharmaceutical Isolator Market Regional Analysis/Insights

The North America pharmaceutical isolator market is analyzed and market size information is provided type, pressure, application, configuration, system type, end user and distribution channel.

The countries covered in this market report U.S., Canada, and Mexico. In 2022, the U.S. is dominating due to the presence of key market players in the largest consumer market with high GDP and rise in technological advancement in agriculture sector.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of North America brands and their challenges faced due to large or scarce competition from local and domestic brands, and impact of sales channels are considered while providing forecast analysis of the country data.

Competitive Landscape and North America Pharmaceutical Isolator Market Share Analysis

North America pharmaceutical isolator market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in R&D, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breath, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus on the North America pharmaceutical isolator market.

Some of the major players operating in the North America pharmaceutical isolator market are Getinge, SKAN AG, Hosokawa micron ltd, Gelman Singapore, Azbil Corporation, Germfree Laboratories, Inc., M. Braun Inertgas-Systeme Gmbh, Nuaire, Iteco S.R.L., Comecer S.P.A., Hecht Technologie Gmbh, Steriline S.R.L., Envair Limited, Tema Sinergie S.P.A, Schematic Engineering Industries, Chiyoda Corporation, Chamunda Pharma Machinery Pvt. Ltd, Bioquell (Ecolab Solution), Jacomex, Fedegari Autoclavi S.p.A., LAF Technologies, ISO Tech Design, Cytiva, Esco Pharma.

Research Methodology: North America Pharmaceutical Isolator Market

Data collection and base year analysis are done using data collection modules with large sample sizes. The market data is analyzed and estimated using market statistical and coherent models. In addition, market share analysis and key trend analysis are the major success factors in the market report. The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, North America vs Regional, and Vendor Share Analysis. Please request analyst call in case of further inquiry.


SKU-

세계 최초의 시장 정보 클라우드 보고서에 온라인으로 접속하세요

  • 대화형 데이터 분석 대시보드
  • 높은 성장 잠재력 기회를 위한 회사 분석 대시보드
  • 사용자 정의 및 질의를 위한 리서치 분석가 액세스
  • 대화형 대시보드를 통한 경쟁자 분석
  • 최신 뉴스, 업데이트 및 추세 분석
  • 포괄적인 경쟁자 추적을 위한 벤치마크 분석의 힘 활용
데모 요청

목차

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF THE NORTH AMERICA PHARMACEUTICAL ISOLATOR MARKET

1.4 CURRENCY AND PRICING

1.5 LIMITATIONS

1.6 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 DBMR TRIPOD DATA VALIDATION MODEL

2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.6 MULTIVARIATE MODELLING

2.7 MARKET APPLICATION COVERAGE GRID

2.8 SOURCE LIFELINE CURVE

2.9 DBMR MARKET POSITION GRID

2.1 VENDOR SHARE ANALYSIS

2.11 SECONDARY SOURCES

2.12 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHT

4.1 PESTEL ANALYSIS

4.2 PORTER’S FIVE FORCES

4.3 INDUSTRIAL INSIGHTS:

5 NORTH AMERICA PHARMACEUTICAL ISOLATORS MARKET: REGULATIONS

6 MARKET OVERVIEW

6.1 DRIVERS

6.1.1 GROWING DEMAND FOR THE PHARMACEUTICAL ISOLATORS ACROSS BOOMING PHARMACEUTICAL

6.1.2 LOW OPERATIONAL COST OF PHARMACEUTICAL ISOLATORS

6.1.3 HIGH MAINTENANCE OF ASEPTIC CONDITIONS IN THE PRODUCTION OF PHARMACEUTICAL PRODUCTS

6.1.4 LOW OPERATING COST OF PHARMACEUTICAL ISOLATORS & GROWING DEMAND IN THE BIOPHARMACEUTICAL INDUSTRY

6.2 RESTRAINTS

6.2.1 STRINGENT GOVERNMENTAL REGULATIONS

6.2.2 HIGH COST OF INSTALLATION & LIMITED ADOPTION OF RABS

6.3 OPPORTUNITIES

6.3.1 STRATEGIC INITIATIVES BY MARKET PLAYERS

6.3.2 TECHNOLOGICAL ADVANCEMENTS IN PHARMACEUTICAL ISOLATORS

6.3.3 HIGH STERILITY ASSURANCE

6.4 CHALLENGES

6.4.1 LACK OF SKILLED EXPERTISE

6.4.2 ENGINEERING CHALLENGES FACED WHILE DESIGNING THE PHARMACEUTICAL ISOLATORS

7 NORTH AMERICA PHARMACEUTICAL ISOLATOR MARKET, BY TYPE

7.1 OVERVIEW

7.2 ASEPTIC ISOLATOR

7.3 ACTIVE PHARMACEUTICAL INGREDIENT (API) MANUFACTURING ISOLATORS

7.4 CONTAINMENT ISOLATORS

7.5 BIO ISOLATORS

7.6 SAMPLING AND WEIGHING ISOLATORS

7.7 RADIOPHARMACEUTICAL ISOLATORS

7.8 PRODUCTION ISOLATORS

7.9 OTHERS

8 NORTH AMERICA PHARMACEUTICAL ISOLATOR MARKET, BY SYSTEM TYPE

8.1 OVERVIEW

8.2 OPEN SYSTEM

8.3 CLOSED SYSTEM

9 NORTH AMERICA PHARMACEUTICAL ISOLATOR MARKET, BY PRESSURE

9.1 OVERVIEW

9.2 POSITIVE PRESSURE

9.3 NEGATIVE PRESSURE

10 NORTH AMERICA PHARMACEUTICAL ISOLATOR MARKET, BY CONFIGURATION

10.1 OVERVIEW

10.2 FLOOR STANDING

10.3 MODULAR

10.4 MOBILE

10.5 COMPACT

10.6 TABLE TOP

10.7 PORTABLE

10.8 OTHERS

11 NORTH AMERICA PHARMACEUTICAL ISOLATOR MARKET, BY APPLICATION

11.1 OVERVIEW

11.2 STERILITY TESTING

11.3 MANUFACTURING

11.4 SAMPLING/WEIGHING/DISTRIBUTION

11.5 MEDICAL DEVICE MANUFACTURING

12 NORTH AMERICA PHARMACEUTICAL ISOLATOR MARKET, BY DISTRIBUTION CHANNEL

12.1 OVERVIEW

12.2 DIRECT TENDER

12.3 RETAIL SALES

12.4 THIRD PARTY DISTRIBUTORS

13 NORTH AMERICA PHARMACEUTICAL ISOLATOR MARKET, BY END USER

13.1 OVERVIEW

13.2 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES

13.2.1 STERILE FILTERING

13.2.2 AMPULE FILLING

13.2.3 SYRINGE FILLING

13.2.4 SAMPLING

13.2.5 SAMPLE TESTING

13.2.6 STERILITY TESTING

13.2.7 PACKAGING

13.2.8 OTHERS

13.3 CONTRACT RESEARCH ORGANIZATION

13.3.1 STERILE FILTERING

13.3.2 AMPULE FILLING

13.3.3 SYRINGE FILLING

13.3.4 SAMPLING

13.3.5 SAMPLE TESTING

13.3.6 STERILITY TESTING

13.3.7 PACKAGING

13.3.8 OTHERS

13.4 ACADEMIC AND RESEARCH INSTITUTES

13.4.1 STERILE FILTERING

13.4.2 AMPULE FILLING

13.4.3 SYRINGE FILLING

13.4.4 SAMPLING

13.4.5 SAMPLE TESTING

13.4.6 STERILITY TESTING

13.4.7 PACKAGING

13.4.8 OTHERS

13.5 HOSPITALS

13.5.1 STERILE FILTERING

13.5.2 AMPULE FILLING

13.5.3 SYRINGE FILLING

13.5.4 SAMPLING

13.5.5 SAMPLE TESTING

13.5.6 STERILITY TESTING

13.5.7 PACKAGING

13.5.8 OTHERS

13.6 DIAGNOSTIC LABORATORIES

13.6.1 STERILE FILTERING

13.6.2 AMPULE FILLING

13.6.3 SYRINGE FILLING

13.6.4 SAMPLING

13.6.5 SAMPLE TESTING

13.6.6 STERILITY TESTING

13.6.7 PACKAGING

13.6.8 OTHERS

13.7 OTHERS

14 NORTH AMERICA PHARMACEUTICAL ISOLATOR MARKET, BY REGION

14.1 NORTH AMERICA

14.1.1 U.S.

14.1.2 CANADA

14.1.3 MEXICO

15 NORTH AMERICA PHARMACEUTICAL ISOLATORS MARKET: COMPANY LANDSCAPE

15.1 COMPANY SHARE ANALYSIS: NORTH AMERICA

16 SWOT ANALYSIS

17 COMPANY PROFILE

17.1 GETINGE AB

17.1.1 COMPANY SNAPSHOT

17.1.2 REVENUE ANALYSIS

17.1.3 COMPANY SHARE ANALYSIS

17.1.4 PRODUCT PORTFOLIO

17.1.5 RECENT DEVELOPMENT

17.2 CYTIVA (A SUBSIDIARY OF DANAHER CORPORATION)

17.2.1 COMPANY SNAPSHOT

17.2.2 REVENUE ANALYSIS

17.2.3 COMPANY SHARE ANALYSIS

17.2.4 PRODUCT PORTFOLIO

17.2.5 RECENT DEVELOPMENT

17.3 AZBIL CORPORATION

17.3.1 COMPANY SNAPSHOT

17.3.2 REVENUE ANALYSIS

17.3.3 COMPANY SHARE ANALYSIS

17.3.4 PRODUCT PORTFOLIO

17.3.5 RECENT DEVELOPMENTS

17.4 CHIYODA CORPORATION

17.4.1 COMPANY SNAPSHOT

17.4.2 REVENUE ANALYSIS

17.4.3 COMPANY SHARE ANALYSIS

17.4.4 PRODUCT PORTFOLIO

17.4.5 RECENT DEVELOPMENT

17.5 HOSOKAWA MICRON LTD

17.5.1 COMPANY SNAPSHOT

17.5.2 COMPANY SHARE ANALYSIS

17.5.3 PRODUCT PORTFOLIO

17.5.4 RECENT DEVELOPMENTS

17.6 BIOQUELL, AN ECOLAB SOLUTION (A SUBSIDIARY OF ECOLAB)

17.6.1 COMPANY SNAPSHOT

17.6.2 REVENUE ANALYSIS

17.6.3 PRODUCT PORTFOLIO

17.6.4 RECENT DEVELOPMENT

17.7 CHAMUNDA PHARMA MACHNIERY

17.7.1 COMPANY SNAPSHOT

17.7.2 PRODUCT PORTFOLIO

17.7.3 RECENT DEVELOPMENTS

17.8 COMECER S.P.A. (A SUBSIDIARY OF ATS AUTOMATION TOOLS) (2021)

17.8.1 COMPANY SNAPSHOT

17.8.2 REVENUE ANALYSIS

17.8.3 PRODUCT PORTFOLIO

17.8.4 RECENT DEVELOPMENT

17.9 ENVAIR TECHNOLOGY

17.9.1 COMPANY SNAPSHOT

17.9.2 PRODUCT PORTFOLIO

17.9.3 RECENT DEVELOPMENTS

17.1 ESCO MICRO PTE. LTD

17.10.1 COMPANY SNAPSHOT

17.10.2 PRODUCT PORTFOLIO

17.10.3 RECENT DEVELOPMENT

17.11 FEDEGARI AUTOCLAVI S.P.A

17.11.1 COMPANY SNAPSHOT

17.11.2 PRODUCT PORTFOLIO

17.11.3 RECENT DEVELOPMENTS

17.12 GERMFREE LABORATORIES, INC.

17.12.1 COMPANY SNAPSHOT

17.12.2 PRODUCT PORTFOLIO

17.12.3 RECENT DEVELOPMENT

17.13 GELMAN SINGAPORE

17.13.1 COMPANY SNAPSHOT

17.13.2 PRODUCT PORTFOLIO

17.13.3 RECENT DEVELOPMENTS

17.14 HECT TECHNOLOGIE GMBH (2021)

17.14.1 COMPANY SNAPSHOT

17.14.2 PRODUCT PORTFOLIO

17.14.3 RECENT DEVELOPMENT

17.15 ISO TECH DESIGN

17.15.1 COMPANY SNAPSHOT

17.15.2 PRODUCT PORTFOLIO

17.15.3 RECENT DEVELOPMENTS

17.16 ITECO SRL

17.16.1 COMPANY SNAPSHOT

17.16.2 PRODUCT PORTFOLIO

17.16.3 RECENT DEVELOPMENT

17.17 JACOMEX

17.17.1 COMPANY SNAPSHOT

17.17.2 PRODUCT PORTFOLIO

17.17.3 RECENT DEVELOPMENT

17.18 LAF TECHNOLOGIES

17.18.1 COMPANY SNAPSHOT

17.18.2 PRODUCT PORTFOLIO

17.18.3 RECENT DEVELOPMENTS

17.19 MBRAUN.(2021)

17.19.1 COMPANY SNAPSHOT

17.19.2 PRODUCT PORTFOLIO

17.19.3 RECENT DEVELOPMENT

17.2 NUAIRE (A SUBSIDIARY OF GENUIT GROUP PLC)

17.20.1 COMPANY SNAPSHOT

17.20.2 REVENUE ANALYSIS

17.20.3 PRODUCT PORTFOLIO

17.20.4 RECENT DEVELOPMENTS

17.21 STERILINE (2021)

17.21.1 COMPANY SNAPSHOT

17.21.2 PRODUCT PORTFOLIO

17.21.3 RECENT DEVELOPMENTS

17.22 SCHEMATIC ENGINEERING INDUSTRY

17.22.1 COMPANY SNAPSHOT

17.22.2 PRODUCT PORTFOLIO

17.22.3 RECENT DEVELOPMENTS

17.23 SKAN AG

17.23.1 COMPANY SNAPSHOT

17.23.2 REVENUE ANALYSIS

17.23.3 PRODUCT PORTFOLIO

17.23.4 RECENT DEVELOPMENT

17.24 TEMA SINERGIE S.P.A

17.24.1 COMPANY SNAPSHOT

17.24.2 PRODUCT PORTFOLIO

17.24.3 RECENT DEVELOPMENTS

18 QUESTIONNAIRE

19 RELATED REPORTS

표 목록

TABLE 1 OPERATING COSTS FOR ASEPTIC PRODUCTION UNDER RABS OR ISOLATOR

TABLE 2 APPLICATION OF GUI-0104 TO API MANUFACTURING

TABLE 3 NORTH AMERICA PHARMACEUTICAL ISOLATOR MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 4 NORTH AMERICA ASEPTIC ISOLATOR IN PHARMACEUTICAL ISOLATOR MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 5 NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENT (API) MANUFACTURING ISOLATORS IN PHARMACEUTICAL ISOLATOR MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 6 NORTH AMERICA CONTAINMENT ISOLATORS IN PHARMACEUTICAL ISOLATOR MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 7 NORTH AMERICA BIO ISOLATORS IN PHARMACEUTICAL ISOLATOR MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 8 NORTH AMERICA SAMPLING AND WEIGHING ISOLATORS IN PHARMACEUTICAL ISOLATOR MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 9 NORTH AMERICA RADIOPHARMACEUTICAL ISOLATORS IN PHARMACEUTICAL ISOLATOR MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 10 NORTH AMERICA PRODUCTION ISOLATORS IN PHARMACEUTICAL ISOLATOR MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 11 NORTH AMERICA OTHERS IN PHARMACEUTICAL ISOLATOR MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 12 NORTH AMERICA PHARMACEUTICAL ISOLATOR MARKET, BY SYSTEM TYPE, 2020-2029 (USD MILLION)

TABLE 13 NORTH AMERICA OPEN SYSTEM IN PHARMACEUTICAL ISOLATOR MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 14 NORTH AMERICA CLOSED SYSTEM IN PHARMACEUTICAL ISOLATOR MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 15 NORTH AMERICA PHARMACEUTICAL ISOLATOR MARKET, BY PRESSURE, 2020-2029 (USD MILLION)

TABLE 16 NORTH AMERICA POSITIVE PRESSURE IN PHARMACEUTICAL ISOLATOR MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 17 NORTH AMERICA NEGATIVE PRESSURE IN PHARMACEUTICAL ISOLATOR MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 18 NORTH AMERICA PHARMACEUTICAL ISOLATOR MARKET, BY CONFIGURATION, 2020-2029 (USD MILLION)

TABLE 19 NORTH AMERICA FLOOR STANDING IN PHARMACEUTICAL ISOLATOR MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 20 NORTH AMERICA MODULAR IN PHARMACEUTICAL ISOLATOR MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 21 NORTH AMERICA MOBILE IN PHARMACEUTICAL ISOLATOR MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 22 NORTH AMERICA COMPACT IN PHARMACEUTICAL ISOLATOR MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 23 NORTH AMERICA TABLE TOP IN PHARMACEUTICAL ISOLATOR MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 24 NORTH AMERICA PORTABLE IN PHARMACEUTICAL ISOLATOR MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 25 NORTH AMERICA OTHERS IN PHARMACEUTICAL ISOLATOR MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 26 NORTH AMERICA PHARMACEUTICAL ISOLATOR MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 27 NORTH AMERICA STERILITY TESTING IN PHARMACEUTICAL ISOLATOR MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 28 NORTH AMERICA MANUFACTURING IN PHARMACEUTICAL ISOLATOR MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 29 NORTH AMERICA SAMPLING/WEIGHING/DISTRIBUTION IN PHARMACEUTICAL ISOLATOR MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 30 NORTH AMERICA MEDICAL DEVICE MANUFACTURING IN PHARMACEUTICAL ISOLATOR MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 31 NORTH AMERICA PHARMACEUTICAL ISOLATOR MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 32 NORTH AMERICA DIRECT TENDER IN PHARMACEUTICAL ISOLATOR MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 33 NORTH AMERICA RETAIL SALES INPHARMACEUTICAL ISOLATOR MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 34 NORTH AMERICA THIRD PARTY DISTRIBUTORS IN PHARMACEUTICAL ISOLATOR MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 35 NORTH AMERICA PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 36 NORTH AMERICA PHARMACEUTICAL AND BIOTECHNOLOGICAL COMPANIES IN PHARMACEUTICAL ISOLATOR MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 37 NORTH AMERICA PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES IN PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 38 NORTH AMERICA CONTRACT RESEARCH ORGANIZATIONS IN PHARMACEUTICAL ISOLATOR MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 39 NORTH AMERICA CONTRACT RESEARCH ORGANIZATIONS IN PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 40 NORTH AMERICA ACADEMIC AND RESEARCH INSTITUTES IN PHARMACEUTICAL ISOLATOR MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 41 NORTH AMERICA ACADEMIC RESEARCH & INSTITUTES IN PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 42 NORTH AMERICA HOSPITALS IN PHARMACEUTICAL ISOLATOR MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 43 NORTH AMERICA HOSPITALS IN PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 44 NORTH AMERICA DIAGNOSTIC LABARATORIES IN PHARMACEUTICAL ISOLATOR MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 45 NORTH AMERICA DIAGNOSTICS LABORATORIES IN PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 46 NORTH AMERICA OTHERS IN PHARMACEUTICAL ISOLATOR MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 47 NORTH AMERICA PHARMACEUTICAL ISOLATOR MARKET, BY COUNTRY, 2020-2029 (USD MILLION)

TABLE 48 NORTH AMERICA PHARMACEUTICAL ISOLATOR MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 49 NORTH AMERICA PHARMACEUTICAL ISOLATOR MARKET, BY SYSTEM TYPE, 2020-2029 (USD MILLION)

TABLE 50 NORTH AMERICA PHARMACEUTICAL ISOLATOR MARKET, BY PRESSURE, 2020-2029 (USD MILLION)

TABLE 51 NORTH AMERICA PHARMACEUTICAL ISOLATOR MARKET, BY CONFIGURATION, 2020-2029 (USD MILLION)

TABLE 52 NORTH AMERICA PHARMACEUTICAL ISOLATOR MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 53 NORTH AMERICA PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 54 NORTH AMERICA PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES IN PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 55 NORTH AMERICA CONTRACT RESEARCH ORGANIZATIONS IN PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 56 NORTH AMERICA ACADEMIC RESEARCH & INSTITUTES IN PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 57 NORTH AMERICA HOSPITALS LABORATORIES IN PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 58 NORTH AMERICA DIAGNOSTICS IN PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 59 NORTH AMERICA PHARMACEUTICAL ISOLATOR MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 60 U.S. PHARMACEUTICAL ISOLATOR MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 61 U.S. PHARMACEUTICAL ISOLATOR MARKET, BY SYSTEM TYPE, 2020-2029 (USD MILLION)

TABLE 62 U.S. PHARMACEUTICAL ISOLATOR MARKET, BY PRESSURE, 2020-2029 (USD MILLION)

TABLE 63 U.S. PHARMACEUTICAL ISOLATOR MARKET, BY CONFIGURATION, 2020-2029 (USD MILLION)

TABLE 64 U.S. PHARMACEUTICAL ISOLATOR MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 65 U.S. PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 66 U.S. PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES IN PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 67 U.S. CONTRACT RESEARCH ORGANIZATIONS IN PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 68 U.S. ACADEMIC RESEARCH & INSTITUTES IN PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 69 U.S. HOSPITALS LABORATORIES IN PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 70 U.S. DIAGNOSTICS IN PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 71 U.S. PHARMACEUTICAL ISOLATOR MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 72 CANADA PHARMACEUTICAL ISOLATOR MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 73 CANADA PHARMACEUTICAL ISOLATOR MARKET, BY SYSTEM TYPE, 2020-2029 (USD MILLION)

TABLE 74 CANADA PHARMACEUTICAL ISOLATOR MARKET, BY PRESSURE, 2020-2029 (USD MILLION)

TABLE 75 CANADA PHARMACEUTICAL ISOLATOR MARKET, BY CONFIGURATION, 2020-2029 (USD MILLION)

TABLE 76 CANADA PHARMACEUTICAL ISOLATOR MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 77 CANADA PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 78 CANADA PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES IN PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 79 CANADA CONTRACT RESEARCH ORGANIZATIONS IN PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 80 CANADA ACADEMIC RESEARCH & INSTITUTES IN PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 81 CANADA HOSPITALS LABORATORIES IN PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 82 CANADA DIAGNOSTICS IN PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 83 CANADA PHARMACEUTICAL ISOLATOR MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 84 MEXICO PHARMACEUTICAL ISOLATOR MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 85 MEXICO PHARMACEUTICAL ISOLATOR MARKET, BY SYSTEM TYPE, 2020-2029 (USD MILLION)

TABLE 86 MEXICO PHARMACEUTICAL ISOLATOR MARKET, BY PRESSURE, 2020-2029 (USD MILLION)

TABLE 87 MEXICO PHARMACEUTICAL ISOLATOR MARKET, BY CONFIGURATION, 2020-2029 (USD MILLION)

TABLE 88 MEXICO PHARMACEUTICAL ISOLATOR MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 89 MEXICO PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 90 MEXICO PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES IN PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 91 MEXICO CONTRACT RESEARCH ORGANIZATIONS IN PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 92 MEXICO ACADEMIC RESEARCH & INSTITUTES IN PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 93 MEXICO HOSPITALS LABORATORIES IN PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 94 MEXICO DIAGNOSTICS IN PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 95 MEXICO PHARMACEUTICAL ISOLATOR MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

그림 목록

FIGURE 1 NORTH AMERICA PHARMACEUTICAL ISOLATOR MARKET: SEGMENTATION

FIGURE 2 NORTH AMERICA PHARMACEUTICAL ISOLATOR MARKET: DATA TRIANGULATION

FIGURE 3 NORTH AMERICA PHARMACEUTICAL ISOLATOR MARKET: DROC ANALYSIS

FIGURE 4 NORTH AMERICA PHARMACEUTICAL ISOLATOR MARKET: REGIONAL VS COUNTRY MARKET ANALYSIS

FIGURE 5 NORTH AMERICA PHARMACEUTICAL ISOLATOR MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 NORTH AMERICA PHARMACEUTICAL ISOLATOR MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 NORTH AMERICA PHARMACEUTICAL ISOLATOR MARKET: MARKET APPLICATION COVERAGE GRID

FIGURE 8 NORTH AMERICA PHARMACEUTICAL ISOLATOR MARKET: DBMR MARKET POSITION GRID

FIGURE 9 NORTH AMERICA PHARMACEUTICAL ISOLATOR MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 NORTH AMERICA PHARMACEUTICAL ISOLATOR MARKET: SEGMENTATION

FIGURE 11 INCREASING USE OF PHARMACEUTICAL ISOLATORS IS EXPECTED TO DRIVE THE NORTH AMERICA PHARMACEUTICAL ISOLATOR MARKET IN THE FORECAST PERIOD OF 2022 TO 2029

FIGURE 12 ASEPTIC ISOLATORS IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA PHARMACEUTICAL ISOLATOR MARKET IN 2022 & 2029

FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE NORTH AMERICA PHARMACEUTICAL ISOLATOR MARKET

FIGURE 14 NORTH AMERICA PHARMACEUTICAL ISOLATOR MARKET: BY TYPE, 2021

FIGURE 15 NORTH AMERICA PHARMACEUTICAL ISOLATOR MARKET: BY TYPE, 2022-2029 (USD MILLION)

FIGURE 16 NORTH AMERICA PHARMACEUTICAL ISOLATOR MARKET: BY TYPE, CAGR (2022-2029)

FIGURE 17 NORTH AMERICA PHARMACEUTICAL ISOLATOR MARKET: BY TYPE, LIFELINE CURVE

FIGURE 18 NORTH AMERICA PHARMACEUTICAL ISOLATOR MARKET: BY SYSTEM TYPE, 2021

FIGURE 19 NORTH AMERICA PHARMACEUTICAL ISOLATOR MARKET: BY SYSTEM TYPE, 2022-2029 (USD MILLION)

FIGURE 20 NORTH AMERICA PHARMACEUTICAL ISOLATOR MARKET: BY SYSTEM TYPE, CAGR (2022-2029)

FIGURE 21 NORTH AMERICA PHARMACEUTICAL ISOLATOR MARKET: BY SYSTEM TYPE, LIFELINE CURVE

FIGURE 22 NORTH AMERICA PHARMACEUTICAL ISOLATOR MARKET: BY PRESSURE, 2021

FIGURE 23 NORTH AMERICA PHARMACEUTICAL ISOLATOR MARKET: BY PRESSURE, 2022-2029 (USD MILLION)

FIGURE 24 NORTH AMERICA PHARMACEUTICAL ISOLATOR MARKET: BY PRESSURE, CAGR (2022-2029)

FIGURE 25 NORTH AMERICA PHARMACEUTICAL ISOLATOR MARKET: BY PRESSURE, LIFELINE CURVE

FIGURE 26 NORTH AMERICA PHARMACEUTICAL ISOLATOR MARKET: BY CONFIGURATION, 2021

FIGURE 27 NORTH AMERICA PHARMACEUTICAL ISOLATOR MARKET: BY CONFIGURATION, 2022-2029 (USD MILLION)

FIGURE 28 NORTH AMERICA PHARMACEUTICAL ISOLATOR MARKET: BY CONFIGURATION, CAGR (2022-2029)

FIGURE 29 NORTH AMERICA PHARMACEUTICAL ISOLATOR MARKET: BY CONFIGURATION, LIFELINE CURVE

FIGURE 30 NORTH AMERICA PHARMACEUTICAL ISOLATOR MARKET: BY APPLICATION, 2021

FIGURE 31 NORTH AMERICAPHARMACEUTICAL ISOLATOR MARKET: BY APPLICATION, 2022-2029 (USD MILLION)

FIGURE 32 NORTH AMERICA PHARMACEUTICAL ISOLATOR MARKET: BY APPLICATION, CAGR (2022-2029)

FIGURE 33 NORTH AMERICA PHARMACEUTICAL ISOLATOR MARKET: BY APPLICATION, LIFELINE CURVE

FIGURE 34 NORTH AMERICA PHARMACEUTICAL ISOLATOR MARKET: BY DISTRIBUTION CHANNEL, 2021

FIGURE 35 NORTH AMERICAPHARMACEUTICAL ISOLATOR MARKET: BY DISTRIBUTION CHANNEL, 2022-2029 (USD MILLION)

FIGURE 36 NORTH AMERICAPHARMACEUTICAL ISOLATOR MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029)

FIGURE 37 NORTH AMERICAPHARMACEUTICAL ISOLATOR MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 38 NORTH AMERICA PHARMACEUTICAL ISOLATOR MARKET : BY END USER, 2021

FIGURE 39 NORTH AMERICA PHARMACEUTICAL ISOLATOR MARKET : BY END USER, 2022-2029 (USD MILLION)

FIGURE 40 NORTH AMERICA PHARMACEUTICAL ISOLATOR MARKET : BY END USER, CAGR (2022-2029)

FIGURE 41 NORTH AMERICA PHARMACEUTICAL ISOLATOR MARKET : BY END USER, LIFELINE CURVE

FIGURE 42 NORTH AMERICA PHARMACEUTICAL ISOLATOR MARKET: SNAPSHOT (2021)

FIGURE 43 NORTH AMERICA PHARMACEUTICAL ISOLATOR MARKET: BY COUNTRY (2021)

FIGURE 44 NORTH AMERICA PHARMACEUTICAL ISOLATOR MARKET: BY COUNTRY (2022 & 2029)

FIGURE 45 NORTH AMERICA PHARMACEUTICAL ISOLATOR MARKET: BY COUNTRY (2021 & 2029)

FIGURE 46 NORTH AMERICA PHARMACEUTICAL ISOLATOR MARKET: TYPE (2022-2029)

FIGURE 47 NORTH AMERICA PHARMACEUTICAL ISOLATORS MARKET: COMPANY SHARE 2021 (%)

자세한 정보 보기 Right Arrow

연구 방법론

데이터 수집 및 기준 연도 분석은 대규모 샘플 크기의 데이터 수집 모듈을 사용하여 수행됩니다. 이 단계에는 다양한 소스와 전략을 통해 시장 정보 또는 관련 데이터를 얻는 것이 포함됩니다. 여기에는 과거에 수집한 모든 데이터를 미리 검토하고 계획하는 것이 포함됩니다. 또한 다양한 정보 소스에서 발견되는 정보 불일치를 검토하는 것도 포함됩니다. 시장 데이터는 시장 통계 및 일관된 모델을 사용하여 분석하고 추정합니다. 또한 시장 점유율 분석 및 주요 추세 분석은 시장 보고서의 주요 성공 요인입니다. 자세한 내용은 분석가에게 전화를 요청하거나 문의 사항을 드롭하세요.

DBMR 연구팀에서 사용하는 주요 연구 방법론은 데이터 마이닝, 시장에 대한 데이터 변수의 영향 분석 및 주요(산업 전문가) 검증을 포함하는 데이터 삼각 측량입니다. 데이터 모델에는 공급업체 포지셔닝 그리드, 시장 타임라인 분석, 시장 개요 및 가이드, 회사 포지셔닝 그리드, 특허 분석, 가격 분석, 회사 시장 점유율 분석, 측정 기준, 글로벌 대 지역 및 공급업체 점유율 분석이 포함됩니다. 연구 방법론에 대해 자세히 알아보려면 문의를 통해 업계 전문가에게 문의하세요.

사용자 정의 가능

Data Bridge Market Research는 고급 형성 연구 분야의 선두 주자입니다. 저희는 기존 및 신규 고객에게 목표에 맞는 데이터와 분석을 제공하는 데 자부심을 느낍니다. 보고서는 추가 국가에 대한 시장 이해(국가 목록 요청), 임상 시험 결과 데이터, 문헌 검토, 재생 시장 및 제품 기반 분석을 포함하도록 사용자 정의할 수 있습니다. 기술 기반 분석에서 시장 포트폴리오 전략에 이르기까지 타겟 경쟁업체의 시장 분석을 분석할 수 있습니다. 귀하가 원하는 형식과 데이터 스타일로 필요한 만큼 많은 경쟁자를 추가할 수 있습니다. 저희 분석가 팀은 또한 원시 엑셀 파일 피벗 테이블(팩트북)로 데이터를 제공하거나 보고서에서 사용 가능한 데이터 세트에서 프레젠테이션을 만드는 데 도움을 줄 수 있습니다.

자주 묻는 질문

The North America Pharmaceutical Isolator Market is projected to grow at a CAGR of 14.6% during the forecast period by 2029.
The future market value of the North America Pharmaceutical Isolator Market is expected to reach USD 2,627.64 million by 2029.
The major players in the North America Pharmaceutical Isolator Market are Getinge, SKAN AG, Hosokawa micron ltd, Gelman Singapore, Azbil Corporation, Germfree Laboratories, Inc., M. Braun Inertgas-Systeme Gmbh, Nuaire, Iteco S.R.L., Comecer S.P.A., Hecht Technologie Gmbh, Steriline S.R.L., Envair Limited, Tema Sinergie S.P.A, etc.
The country covered in the North America Pharmaceutical Isolator Market is U.S., Canada, and Mexico.